Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor

29 Mar 2021

Abstract excerpt

The management of the rare, life threatening and chronic disease, paroxysmal nocturnal hemoglobinuria (PNH) was revolutionized by the introduction of the terminal complement inhibitor therapy, eculizumab (Soliris), which was licensed in 2007.1 Since that time, numerous studies have highlighted the improvement in organ damage on a C5 inhibitor, such as reduction in thrombotic events, improvement in renal function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Complement system in diseases
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33780028
DOI: 10.1002/ajh.26176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorPMID 33780028Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

[Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].Semantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Biology and TreatmentSemantic proximity Read ↗

Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype.Semantic proximity Read ↗

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.